Business Wire

IL-PRICEFX

28.1.2021 15:32:13 CET | Business Wire | Press release

Share
Pricefx Partners with Bain & Company to Launch the Pricing Industry’s First Big Data Powered Benchmarking Platform

Pricefx , the global leader in cloud-native pricing software, today launched PricefxPlasma™, the first big data powered benchmarking platform for the pricing industry. Powered by Bain & Company , PricefxPlasma leverages real world pricing data mapped to industry standard key performance indicators (KPIs). Businesses can discover strategic insights on their own pricing processes and performance as compared to market averages using benchmarks on a pre-defined set of industry relevant KPIs.

“Every company is looking for an edge over the competition and pricing is one of the strongest levers for success in the marketplace,” said Marcin Cichon, CEO and co-founder at Pricefx. “By launching the first pricing analytics and intelligence platform via a joint project with our valued partners at Bain, Pricefx is giving its customers a whole new level of cross-industry insights. PricefxPlasma is a revolutionary new offering for the pricing industry, providing businesses the information and insights to improve pricing efficiency and effectiveness and uncover new opportunities for revenue growth.”

PricefxPlasma combines a massive amount of anonymized and aggregated transaction and quoting data from industries, sliced and segmented by region, industry and other factors. Data is then compiled into more than 20 pricing performance benchmarks, delivered in intuitive visual outputs and designed to answer the most important pricing analytics questions.

KPIs currently measured in PricefxPlasma include:

  • End-to-end price waterfall: detailed price buildup, including on- and off-invoice discounts, cost elements, geographical prices, list prices and margin elements.
  • Deal approval process: deal velocity, the percent of deals outside discount guidelines, the number of steps in the approval process.
  • Price setting: the value capture of price increases, the number of list price changes per year.
  • Measures of customer and product concentration: the percent of customers/products to reach revenue deciles.

Companies often struggle to understand how their pricing practices measure up to industry best practices. Additionally, according to a Bain & Company survey , many B2B companies do not provide their salesforce with the right tools and data to make effective pricing decisions.

“Companies typically assess the effectiveness of their pricing strategy and execution using a combination of anecdotal data, generic or poorly defined benchmarks, and a lot of guesswork,” said Robert Kugel, Senior Vice President and Research Director at Ventana Research. “Having reliable industry benchmarks derived from real world data provides businesses valuable insight to how they measure up to their peers. PricefxPlasma is an attempt to make useful benchmarks readily available and consumable. Having reliable pricing data also can help businesses identify market trends that enable them to make better decisions about strategy, investments and products.”

How PricefxPlasma Works

Pricefx gathers, anonymizes and aggregates its customers’ data into standardized metrics. These metrics are loaded into the PricefxPlasma platform, which aggregates and filters the metrics further to create industry-level benchmarks. The customer's data is anonymized by Pricefx via double-blinding, ensuring that it is impossible to trace individual customer data.

Industry benchmarks are compiled from aggregated metrics from a number of anonymized entities. The resulting benchmarks are distributed to Pricefx’s customers’ environment. Customers can view these benchmarks through a set of standard Pricefx dashboards and customers can also include this data in their own dashboards, allowing for a direct comparison between their company and the benchmark. Benchmarks may be filtered by industry and region to arrive at the desired peer set.

Pricefx partnered with Bain & Company, a global management consulting firm, to develop the benchmarking capabilities and IT systems.

“Combining Pricefx’s world-class pricing software with best practices from Bain’s Pricing and Benchmarking Centers of Excellence, PricefxPlasma provides unique pricing insights never before available that compare your pricing processes and performance to peers,” said Ron Kermisch, Partner at Bain & Company. “Together, we discovered a way to aggregate massive amounts of valuable data and synthesize that data into market relevant KPIs for B2B enterprises to unlock data-driven insights and create a business advantage.”

Pricefx and Bain & Company previously collaborated to launch price Accelerators and the Bain Pricing Navigator powered by Pricefx. Pricefx is a member of the Bain Alliance Ecosystem – a network of best-of-breed partnerships with complementary tool, technology and service providers that accelerates delivery of breakthrough client results.

Availability

PricefxPlasma is available now and is free of charge to Pricefx customers. More information can be found at www.pricefx.com/pricefxplasma . Insights from the platform will also be available to Bain clients and more information can be found at www.bain.com/pricefxplasma .

About Bain & Company

Bain & Company is a global consultancy that helps the world’s most ambitious change makers define the future. Across 59 offices in 37 countries, we work alongside our clients as one team with a shared ambition to achieve extraordinary results, outperform the competition and redefine industries. We complement our tailored, integrated expertise with a vibrant ecosystem of digital innovators to deliver better, faster and more enduring outcomes. Our 10-year commitment to invest more than $1 billion in pro bono services brings our talent, expertise and insight to organizations tackling today’s urgent challenges in education, racial equity, social justice, economic development and the environment. Since our founding in 1973, we have measured our success by the success of our clients, and we proudly maintain the highest level of client advocacy in the industry.

Learn more at www.bain.com and follow us on Twitter @BainAlerts.

About Pricefx

Established in 2011 in Germany, Pricefx is the global leader in SaaS pricing software, offering a comprehensive suite of solutions that are fast to implement, flexible to configure and customize, and friendly to learn and use. Pricefx delivers a complete price optimization and management platform based on native cloud architecture, providing industry leading time to value and total cost of ownership advantages to customers. Its innovative solution works for both B2B and B2C enterprises of any size, in any industry, in any part of the world. Pricefx’s business model is entirely based on the satisfaction and loyalty of its customers. Today, Pricefx delivers Passion for Pricing to customers in more than 37 countries worldwide. For more information, please visit www.pricefx.com .

PricefxPlasma™ is a trademark of Price f(x) AG.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Danish C-UAS Startup Shotling Raises €700K Oversubscribed Pre-Seed (Myriad-IPO CLUB-EIFO) for Anti-Drone Shotgun2.2.2026 07:35:00 CET | Press release

Shotling, a Danish defense technology startup specializing in kinetic short-range counter-UAS (C-UAS) systems, today announced the closing of a pre-seed financing round with €700K committed out of a targeted €500K. The round is led by Myriad Defense Fund, with co-investment from IPO CLUB’s Fund II America 2030, and a non-dilutive match-loan granted by EIFO, the Export and Investment Fund of Denmark, supporting Shotling’s mission to deliver rapid-fire modular shotgun systems against FPV drones and loitering munitions—as the global counter-UAS market accelerates towards $10B by 2030, with kinetic defense segment showing strong momentum (25%+ CAGR). Shotling’s rotary shotgun system provides unmatched close-range defense (50–100m) against the rapidly growing threat of kamikaze drones, combining a gatling-style design, with novel, high-capacity magazines, and firing rates up to 3,000 RPM using standard or tungsten-based 12-gauge shells. With deep expertise in weapons engineering and active

Galderma Announces U.S. FDA Acceptance of RelabotulinumtoxinA Biologics License Application Resubmission2.2.2026 07:00:00 CET | Press release

The United States (U.S.) Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults RelabotulinumtoxinA is designed to optimize molecule integrity to deliver fast onset of action as early as Day 1 and sustained results for six months for frown lines and crow’s feet and has been approved in over 20 markets, including in the European Union1-3 Galderma (SIX: GALD) today announced that the U.S. FDA has accepted the BLA resubmission for RelabotulinumtoxinA for the temporary improvement of moderate-to-severe glabellar lines (frown lines) and lateral canthal lines (crow’s feet) in adults. Galderma has worked closely with the U.S. FDA to implement adjustments to its manufacturing process. Galderma is committed to using its expertise and heritage in the neuromodulator space to develop next-generation

High-end Aesthetic Brand ‘Lorient’ Gains Global Prestige at IMCAS 20261.2.2026 08:00:00 CET | Press release

Lorient, a premium aesthetic brand, announced that it has drawn global attention at the 27th IMCAS World Congress 2026 in Paris, attracting over 15,000 professionals and demonstrating its leadership in aesthetic innovation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131322203/en/ Lorient’s low degree of modification delivers a smooth injection experience and high biocompatibility (Image: Lorient) The highlight was a session led by Dr. Jani van Loghem, a globally revered key opinion leader known for establishing international aesthetic safety protocols. His involvement provided a prestigious validation of the technical excellence of Lorient. Alongside him, prominent Korean medical experts Dr. Won Lee and Dr. Do Young Rhee shared clinical insights that drew widespread praise from the international medical community. Central to the academic discussions was Lorient’s "safety-first" philosophy for its premium HA filler ran

Sharjah Ruler Receives Portugal’s Grand Collar of Order of Camões31.1.2026 18:27:00 CET | Press release

His Excellency Marcelo Rebelo de Sousa, President of the Portuguese Republic, awarded His Highness Sheikh Dr Sultan bin Mohammed Al Qasimi, Supreme Council Member and Ruler of Sharjah, the Grand Collar of the Order of Camões (Grande Colar da Ordem de Camões), the highest sovereign cultural order in Portugal. His Highness is the first Arab figure to receive the Order of Camões and the sixth recipient worldwide. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260131119526/en/ Sharjah Ruler receives Portugal’s Grand Collar of Order of Camões (Photo: AETOSWire) The honour was conferred during a ceremony hosted by the Portuguese President at the Presidential Palace in Lisbon. The event was attended by Sheikha Bodour bint Sultan Al Qasimi, Chairperson of the Sharjah Book Authority, alongside senior officials. The ceremony recognised His Highness’s prominent global stature, as a leading figure in culture, intellectual thought and in

Incyte Announces Positive CHMP Opinion for Zynyz® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 15:29:00 CET | Press release

Pending the European Commission decision, Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) will be the first PD-1 immunotherapy treatment for patients with advanced squamous cell carcinoma of the anal canal (SCAC) in EuropeGlobally, the prevalence of SCAC is estimated at around 1 or 2 cases per 100,000 people, with a higher incidence in women than in men1,2,3The Committee for Medicinal Products for Human Use (CHMP) positive opinion is based on data from the Phase 3 POD1UM-303/InterAACT2 trial which showed patients with advanced SCAC achieved significantly improved progression-free survival with Zynyz in combination with carboplatin and paclitaxel as a first-line treatment4 Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye